Personalized Medications and Genetic Treatments in Epilepsy

Advances in genomic medicine are reshaping the landscape of epilepsy care, enabling a shift from generalized treatment models to personalized, precision-based approaches. This CME/CE course explores how personalized medications and genetic therapies are transforming seizure management for individuals with epilepsy.

Participants will gain insight into the principles of pharmacogenomics, genotype-phenotype correlations, and the role of next-generation sequencing in guiding diagnosis and therapy. The course highlights specific gene mutations commonly associated with treatment-resistant epilepsy—such as SCN1A, KCNQ2, STXBP1, and CDKL5—and how identifying these variants can inform targeted therapeutic strategies.

Illustrative case studies are used to demonstrate real-world applications of precision therapies, including sodium channel blockers, mTOR inhibitors, and gene-based therapies under clinical investigation. Learners will compare the advantages and limitations of these approaches, including factors such as treatment accessibility, ethical implications, and long-term outcomes.

The course also discusses individualized seizure management plans, taking into account patient genetics, age, seizure type, comorbidities, and medication metabolism. By understanding the interplay between genetics and clinical expression, clinicians can reduce trial-and-error prescribing and improve treatment efficacy and safety.

Designed for neurologists, pediatricians, advanced practice providers, and those working in genetics or clinical pharmacology, this course equips learners with the knowledge and confidence to apply personalized and genetically informed treatment strategies in modern epilepsy care.

Educational Objectives

• Illustrate real-world examples of precision therapies tailored to specific epilepsy syndromes and genetic variants.
• Enhance seizure management by integrating genetic data into individualized treatment planning.
• Compare the benefits and limitations of current and emerging genetic treatments for epilepsy, including safety, efficacy, and accessibility.

Who Should Do This Course?

This course is designed for:

• Neurologists and Epileptologists prescribing advanced therapies and interpreting genetic testing.
• Pediatric Neurologists managing early-onset epilepsies with suspected genetic origins.
• Geneticists and Clinical Pharmacologists applying pharmacogenomic insights to patient care.
• Nurse Practitioners and Physician Assistants involved in epilepsy care and medication monitoring.
• Internal Medicine and Psychiatry professionals managing adult-onset epilepsy with comorbid conditions.

It is especially valuable for clinicians working in epilepsy centers, academic hospitals, or with medically complex patients requiring tailored interventions.

Did You Know?

• Genetic testing can identify a causative mutation in up to 40% of children with early-onset epilepsy. (Neurology Genetics, 2021)
• SCN1A mutations associated with Dravet syndrome require avoidance of sodium channel blockers like carbamazepine. (Epilepsy Currents, 2020)
• Precision therapies like everolimus are FDA-approved for epilepsy in tuberous sclerosis complex. (Lancet Neurology, 2016)
• Whole-exome sequencing yields diagnostic results in up to 50% of epilepsy cases with intellectual disability. (JAMA, 2018)
• Genetic diagnosis can reduce the number of failed medication trials and lead to earlier seizure control. (Pediatrics, 2019)